REMARKS

In general the changes made were to correct grammar and punctuation, to correct claim form, or to bring dependent claims and independent claims in line with one another. The justification for changes other than simple grammatical and punctuation corrections will be described here.

Page 3, line 12

–C(=O)-NH is removed, as it is the second instance of that group under the definition for B the summary of the invention. –C(=O)- was added since it is present as a definition for B in dependent claim 8.

Page 3, line 16

The following groups were added to the definition for J in the summary of the invention: -NH-C(=O)-CH(C_1-C_6alkyl)-, -NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-, -(C_2-C_6alkyl)-, -CH_2-CH_2-, -CH_2NH-, -CH_2-NH-C(=O)-, -CH_2-NH-C(=O)-C_1-C_6alkyl-, -CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-. Support for adding the first two groups can be found in claim 10, which depends from claim 1 and contains definitions for B-J, and can also be found in the corresponding part of the specification, page 10, lines 1-2. Since according to claim 10, B-J can be –C(=O)-CH_2-NH-C(=O)-CH(C_1-C_6alkyl)-, and since –C(=O)-CH_2- is listed as a definition of B in claim 1, then J can be –NH-C(=O)-CH(C_1-C_6alkyl)-. Likewise, since according to claim 10, and page 10 lines 1-2 of the specification, B-J can be –C(=O)-CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-, and since –C(=O)-CH_2- is listed as a definition of B in claim 1, then J can be –NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-. Support for adding the –(C_2-C_6alkyl)- also comes from a B-J definition claim 10, and the corresponding part of the specification page 10, line 2. Since B-J can be –C(=O)-NH-(C_2-C_6alkyl)-, and B can be –C(=O)-NH-, as defined in claim 1, then it follows that J can be define as –(C_2-C_6alkyl)-. Support for the remaining five additions can be found in claim 9, and in the corresponding part of the specification, page 9, lines 17 and 18.

Page 3, line 18

-O- was added to the definition of L; the justification for this addition can be found in claim 7, page 92, line 14, and from the corresponding part of the specification, page 9, line 15.

Page 5, lines 11 and 12

Two groups in the definition for R^9, which is itself a terminal group, have an terminal –NR^{13} with an unspecified third bond to the nitrogen. It is understood in the art that any unspecified group needed to satisfy a valency is hydrogen. Therefore -C(=NR^{12})-NR^{13} was replaced with -C(=NR^{12})-NHR^{13}, and -NR^{13}-C(=NR^{12})-NR^{13} was replaced with -NR^{13}-C(=NR^{12})-NHR^{13}.

Page 9, line 9

Under the description of R^1, "lower alkyl" was replaced with "–(C_1-C_6alkyl)". Justification for this change is found in the definition of R^1 under claim 1, page 89, line 16.

Page 9, line 10

Under the common definition for R^2 and R^3, "lower alkyl" was replaced with C_1-C_6alkyl. Support for the change can be found in the common definition for R^2 and R^3 in claim 1, page 89, line 19.

Page 10, lines 9-11

Structures having R^3 substituents were changed to have R^2 substituents. Support for the change can be found in claim 1, page 89, lines 6-11, and in the corresponding part of the specification, page 4 lines 6-11, where it is stated that M may have optional substituents, the optional substituents being up to three groups selected from R^1, R^2, and R^9." This change is formal only, in that R^2 and R^3 have identical definitions throughout the application, e.g, in claim 1, page 89, lines 18-22.

CLAIMS

Claim 1, page 88, line 12

The changes here are exactly the same as those made for Page 3, line 12. –C(=O)-NH is removed, as it is the second instance of that group under the definition for B in the claim. –C(=O)- was added since it is present as a definition for B in dependent claim 8.

Claim 1, page 88, line 16

The changes here are exactly the same as those made for Page 3, line 16. The following groups were added under the definition for J: -NH-C(=O)-CH(C_1-C_6alkyl)-, -NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-, -(C_2-C_6alkyl)-, -CH_2-CH_2-, -CH_2NH-, -CH_2-NH-C(=O)-, -CH_2-NH-C(=O)-C_1-C_6alkyl-, -CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-. Support for adding the first two groups can be found in claim 10, which depends from claim 1 and contains definitions for B-J, and can also be found in the corresponding part of the specification, page 10, lines 1-2. Since according to claim 10, B-J can be –C(=O)-CH_2-NH-C(=O)-CH(C_1-C_6alkyl)-, and since –C(=O)-CH_2- is listed as a definition of B in claim 1, then J can be –NH-C(=O)-CH(C_1-C_6alkyl)-. Likewise, since according to claim 10, and page 10 lines 1-2 of the specification, B-J can be –C(=O)-CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-, and since –C(=O)-CH_2- is listed as a definition of B in claim 1, then J can be –NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-. Support for adding the –(C_2-C_6alkyl)- also comes from a B-J definition claim 10, and the corresponding part of the specification page 10, line 2. Since B-J can be –C(=O)-NH-(C_2-C_6alkyl)-, and B can be –C(=O)-NH-, as defined in claim 1, then it follows that J can be define as –(C_2-C_6alkyl)-. Support for the remaining five additions can be found in claim 9, and in the corresponding part of the specification, page 9, lines 17 and 18.

Claim 1, page 89, line 14

"1*H*-tetrazol-5-yl" was replaced with "tetrazolyl". Support for the change can be found in claim 7, which is dependent from claim 1 and states that Q may be "tetrazole", which was grammatically corrected to the "tetrazolyl" group. The same support can be found on page 9, line 15 of the specification.

Claim 1, page 90, lines 11 and 12

Identical changes were made here to those in the specification page 5, lines 11 and 12 and the support therefor is described under that heading.

Claim 5, page 92, line 6

The identical change was made here as was made for page 9, line 9 of the specification, and the support therefor is described under that heading.

Claim 6, page 92, line 8

The identical change was made here as was made for page 9, line 10 of the specification, and the support therefor is described under that heading.

Claim 7, page 92, line 11

The term "especially" was replaced with "and" and the term "preferences" was replaced with "conditions" in order to bring the claim into proper form.

Claim 7, page 92, lines 13-14

Under the definition for Q "a negatively charged species such as carboxy or a prodrug thereof" was replaced with "$-C(=O)OR^{16}$". Support for the change can be found in claim 1, page 89, line 12, and on page 4, line 12 of the specification.

Claim 7, page 92, line 14

The term "tetrazole" was grammatically corrected to "tetrazolyl". This impacted the change made to claim 1, page 89, line 14.

Claim 11, page 93, lines 6-8

The same changes were made to this claim as were made for page 10, lines 9-11 of the specification, and the justification therefor can be found under that heading.

No new matter has been added and entry of the amendment is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 405422000600.

Respectfully submitted,

Dated: December 16, 2002 By: _____

Carolyn A. Favorito
Registration No. 39,183

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5195
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Amend the paragraphs commencing on Page 3, line 1, through page 5, line 25, as follows:

SUMMARY OF THE INVENTION

In a first aspect, this invention is compounds of formula I or formula I'



I



I'

where:

m is an integer selected from 0, 1, and 2;

n and o are integers independently selected from 0 and 1;

A is selected from the group consisting of N and CH;

B is selected from the group consisting of $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, -C(=O)-NH-, -C(=O)-CH_2-, $-CH_2-C(=O)-NH-$, $-C(=O)-CH_2-C(=O)-$, $-C(=O)-NH-CH_2-$, [-C(=O)-NH-]-C(=O)-, -S(=O)-, $-S(=O)_2-$, $-S(=O)-NH-$, $-S(=O)_2-NH-$, $-S(=O)-CH_2-$, $-S(=O)_2CH_2-$, $-S(=O)-CH_2-NH-$, $-S(=O)_2-CH_2-NH-$, $-S(=O)_2-NH-CH_2-$, $-CH_2-S(=O)_2-NH-$, $-C(=O)-NH-S(=O)_2-$, $-S(=O)_2-NH-C(=O)-$,

-C(=O)-CH_2-S(=O)$_2$-, and –S(=O)$_2$-CH_2-C(=O)-;

J is absent or selected from the group consisting of –O-, -S-, -CHR^{15}-O-, -CH_2-CHR^{15}-O-, -NH-, -NH-CHR^{15}-, -NH-CHR^{15}-C(=O)-, -C(=O)-, -CH_2-, -CHR^{15}-CH_2-NH-, -C(=O)-CHR^{15}-, -NH-C(=O)-CH(C_1-C_6alkyl)-, -NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-, -CH_2-CH_2-, -CH_2NH-, -CH_2-NH-C(=O)-, -CH_2-NH-C(=O)-C_1-C_6alkyl-, -CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)- and –C(=O)-CHR^{15}-NH-;

L is selected from the group consisting of –O-, –CH_2-O-, -O-CH_2-, -CH_2-CH_2-O-, -O-CH_2-CH_2-, -CH_2-O-CH_2-, -CH_2-S-CH_2-, -C(=O)-NH-, -O-C(=O)-NH-, -CH_2-C(=O)-NH-, -C(=O)-CH_2-NH-, -C(=O)-NH-CH_2-, -NH-C(=O)-, NH-C(=O)-O-, -NH-CH_2-C(=O)-, -NH-C(=O)-CH_2-, -CH_2-NH-C(=O)-, -NH-C(=O)-NH-, -NH-S(=O)$_2$-NH-, -NH-S(=O)$_2$-, -NH-S(=O)$_2$-CH_2-, -CH_2-NH-S(=O)$_2$-, -S(=O)$_2$-NH-, -S(=O)$_2$-NH-CH_2-, -CH_2-S(=O)$_2$-NH-, -C(=O)-NH-S(=O)$_2$-, -S(=O)$_2$-NH-C(=O)-, -CH_2-NH-, -CH_2-CH_2-NH-, -NH-CH_2-, -NH-CH_2-CH_2-, -CH_2-NH-CH_2-, -C≡C-, -CH_2-C≡C-, -CH_2-CH_2-, -CH_2-CH_2-CH_2-, -CH_2-CH=CH-, CH=CH-CH_2-, and –CH=CH-;

M is selected from the group consisting of R^9 and an optionally substituted group selected from phenyl, naphthyl, C_3-C_7-cycloalkyl, and heterocyclyl, the heterocyclyl group being aliphatic, partially unsaturated, or aromatic, and containing 1 or 2 rings each containing 5-7 ring atoms of which 0-3 are hetero atoms selected from N, O and S, provided that at least one ring contains a heteroatom and where any ring carbon or sulfur may optionally be oxidized, the optional substituents being up to three groups selected from R^1, R^2 and R^9;

Q is selected from the group consisting of –C(=O)OR^{16}, -C(=O)-NH-C(=O)-CF_3, -C(=O)-NH-S(=O)$_2$-R^2, -C(=O)-NR^1-OH, 5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl, and [1*H*-tetrazol-5-yl]tetrazolyl;

X is A when n is 1, and is CH, N, O or S when n is 0;

R^1 is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, halo-(C_1-C_6)alkyl, and (C_3-C_6)cycloalkyl;

R^2, R^3 and R^5 are individually selected from the group consisting of hydrogen, cyano, nitro, phenyl, phenoxy, benzyl, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, hydroxy, C_1-C_2alkoxy-methoxy, hydroxy-C_1-C_6alkyl, formyl, C_1-C_6alkylcarbonyl, amino, C_1-C_6alkylamino, aminocarbonyl, C_1-C_6alkylaminocarbonyl, formylamino, and C_1-C_6alkylcarbonylamino, where any alkyl or phenyl may optionally substituted with halo or Q;

R^4 is selected from the group consisting of R^2 and 

where Ar is a homo- or hetero-aryl group having 1 or 2 rings, each ring containing 5, 6 or 7 ring atoms of which 1-3 may be heteroatoms selected from N, O and S;

R^6 is selected from the group consisting of hydrogen, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl; [or]

R^7 is selected from the group consisting of hydrogen, C_1-C_6 alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl;

$R^{7'}$ is hydrogren; or

R^7 and $R^{7'}$ together with the carbon to which they are bonded form –C(=O)-;

R^8 is selected from the group consisting of hydrogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, and C_3-C_6cycloalkyl;

R^9 is selected from the group consisting of $-NR^{10}R^{11}$, $[-C(=NR^{12})-NR^{13}]$-$C(=NR^{12})$-NHR^{13}, $-N=CR^{14}-NR^{10}R^{11}$, $-NR^{13}-CR^{14}=NR^{12}$, and $[-NR^{13}-C(=NR^{12})-NR^{13}]$-$NR^{13}$-$C(=NR^{12})$-$NHR^{13}$;

R^{10}, R^{11}, R^{12}, R^{13} and R^{14} are independently selected from the group consisting of hydrogen, hydroxy, hydroxy-C_1-C_6alkyl, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, and [C_3-C_7 cycloalkyl] C_3-C_7cycloalkyl; or any member of the group R^{10}, R^{11}, R^{12}, R^{13}, and R^{14} together with the nitrogen to which it is attached forms a 5, 6 or 7 member heterocycle with any other member of the group, the heterocycle optionally containing one additional heteroatom selected from N, O [or]and S;

R^{15} is selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_3-C_7cycloalkyl, aminocarbonyl, C_1-C_6alkylaminocarbonyl, and di(C_1-C_6alkyl)aminocarbonyl; and

R^{16} is selected from the group consisting of hydrogen, C_1-C_6alkyl, C_3-C_{13}cycloalkyl, C_6-C_{10}aryl, acetylamino-C_1-C_{12}alkyl, C_1-C_6alkylcarbonyloxy-C_1-C_6alkyl, and C_6-C_{10}aryl-C_0-C_6alkylcarbonyloxy-C_1-C_6alkyl,

or a pharmaceutically acceptable salt thereof;

provided that the compound is not N-[2-[1-(aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-phenylethynyl-phenylalanine methyl ester or a pharmaceutically acceptable salt thereof.

Amend the paragraphs commencing on Page 9, line 8, through page 10, line 4, as follows:

Presently preferred classes of compounds of this invention include those where:

(1) R^1 is hydrogen or [lower alkyl](C_1-C_6alkyl), especially methyl;

(2) R^2 and R^3 are hydrogen, [lower alkyl]C_1-C_6alkyl, cyano, or halo (especially chloro)[;], and more preferably one or both are chloro;

(3) R^4 is 

, especially where one or more of the following preferences applies: Ar is selectd form the group consisting of phenyl, furyl, thienlyl, oxazolyl, thiazolyl, and pyrrolyl; R^5 is hydroxy, C_1-C_2alkoxy-methoxy [and]or C_1-C_3-alkoxy; Q is a negatively charged species such as carboxy (or a prodrug thereof) or [tetrazole]tetrazolyl; and L is –O-, -CH_2-O-, -O-CH_2-, or –CH_2-CH_2-O-[.];

(4) B is –C(=O)- or –$S(=O)_2$-[.];

(5) J is –CH_2-, -CH_2-CH_2-, -NH-, -NH-CH_2-, -CH_2-NH-, -CH_2-NH-C(=O)-, -CH_2-NH-C(=O)-C_1-C_6alkyl- and –CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-[.];

(6) B-J combinations are –C(=O)-CH_2-NH-C(=O)-CH(C_1-C_6alkyl)-, -C(=O)-CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-, -C(=O)-NH-(C_2-C_6alkyl)-, -$S(=O)_2$-NH-(C_2-C_6alkyl)-, -C(=O)-NH-, -$S(=O)_2$-NH-, -C(=O)-CH_2- and –$S(=O)_2$-CH_2-[.];

(7) M is selected from the group consisting of R^9,

Replace the data on Page 10, lines 5-11, with the following data:



and



 ,



and

 ;

In the Claims:

Amend Claim 1 as follows:

1. (Amended) A compound of formula I or formula I'



I



I'

where:

m is an integer selected from 0, 1, and 2;

n and o are integers independently selected from 0 and 1;

A is selected from the group consisting of N and CH;

B is selected from the group consisting of $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-C(=O)-NH-$, $-C(=O)-CH_2-$, $-CH_2-C(=O)-NH-$, $-C(=O)-CH_2-C(=O)-$, $-C(=O)-NH-CH_2-$, [$-C(=O)-NH-$] $-C(=O)-$, $-S(=O)-$, $-S(=O)_2-$, $-S(=O)-NH-$, $-S(=O)_2-NH-$, $-S(=O)-CH_2-$, $-S(=O)_2CH_2-$, $-S(=O)-CH_2-NH-$, $-S(=O)_2-CH_2-NH-$, $-S(=O)_2-NH-CH_2-$, $-CH_2-S(=O)_2-NH-$, $-C(=O)-NH-S(=O)_2-$, $-S(=O)_2-NH-C(=O)-$, $-C(=O)-CH_2-S(=O)_2-$, and $-S(=O)_2-CH_2-C(=O)-$;

J is absent or selected from the group consisting of $-O-$, $-S-$, $-CHR^{15}-O-$, $-CH_2-CHR^{15}-O-$, $-NH-$, $-NH-CHR^{15}-$, $-NH-CHR^{15}-C(=O)-$, $-C(=O)-$, $-CH_2-$, $-CHR^{15}-CH_2-NH-$, $-C(=O)-CHR^{15}-$, $-NH-C(=O)-CH(C_1-C_6alkyl)-$, $-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-$, $-CH_2-CH_2-$, -

CH_2NH-, -CH_2-NH-C(=O)-, -CH_2-NH-C(=O)-C_1-C_6alkyl-, -CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)- and –C(=O)-CHR^{15}-NH-;

L is selected from the group consisting of –O-, –CH_2-O-, -O-CH_2-, -CH_2-CH_2-O-, -O-CH_2-CH_2-, -CH_2-O-CH_2-, -CH_2-S-CH_2-, -C(=O)-NH-, -O-C(=O)-NH-, -CH_2-C(=O)-NH-, -C(=O)-CH_2-NH-, -C(=O)-NH-CH_2-, -NH-C(=O)-, NH-C(=O)-O-, -NH-CH_2-C(=O)-, -NH-C(=O)-CH_2-, -CH_2-NH-C(=O)-, -NH-C(=O)-NH-, -NH-$S(=O)_2$-NH-, -NH-$S(=O)_2$-, -NH-$S(=O)_2$-CH_2-, -CH_2-NH-$S(=O)_2$-, -$S(=O)_2$-NH-, -$S(=O)_2$-NH-CH_2-, -CH_2-$S(=O)_2$-NH-, -C(=O)-NH-$S(=O)_2$-, -$S(=O)_2$-NH-C(=O)-, -CH_2-NH-, -CH_2-CH_2-NH-, -NH-CH_2-, -NH-CH_2-CH_2-, -CH_2-NH-CH_2-, -C≡C-, -CH_2-C≡C-, -CH_2-CH_2-, -CH_2-CH_2-CH_2-, -CH_2-CH=CH-, CH=CH-CH_2-, and –CH=CH-;

M is selected from the group consisting of R^9 and an optionally substituted group selected from phenyl, naphthyl, C_3-C_7-cycloalkyl, and heterocyclyl, the heterocyclyl group being aliphatic, partially unsaturated, or aromatic, and containing 1 or 2 rings each containing 5-7 ring atoms of which 0-3 are hetero atoms selected from N, O and S, provided that at least one ring contains a heteroatom and where any ring carbon or sulfur may optionally be oxidized, the optional substituents being up to three groups selected from R^1, R^2 and R^9;

Q is selected from the group consisting of –C(=O)OR^{16}, -C(=O)-NH-C(=O)-CF_3, -C(=O)-NH-$S(=O)_2$-R^2, -C(=O)-NR^1-OH, 5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl, and [1*H*-tetrazol-5-yl]tetrazolyl;

X is A when n is 1, and is CH, N, O or S when n is 0;

R^1 is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, halo-(C_1-C_6)alkyl, and (C_3-C_6)cycloalkyl;

R^2, R^3 and R^5 are individually selected from the group consisting of hydrogen, cyano, nitro, phenyl, phenoxy, benzyl, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, hydroxy, C_1-C_2alkoxy-methoxy, hydroxy-C_1-C_6alkyl, formyl, C_1-C_6alkylcarbonyl, amino, C_1-C_6alkylamino, aminocarbonyl, C_1-C_6alkylaminocarbonyl, formylamino, and C_1-C_6alkylcarbonylamino, where any alkyl or phenyl may optionally substituted with halo or Q;

R^4 is selected from the group consisting of R^2 and 

where Ar is a homo- or hetero-aryl group having 1 or 2 rings, each ring containing 5, 6 or 7 ring atoms of which 1-3 may be heteroatoms selected from N, O and S;

R^6 is selected from the group consisting of hydrogen, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl; [or]

R^7 is selected from the group consisting of hydrogen, C_1-C_6 alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl;

$R^{7'}$ is hydrogren; or

R^7 and $R^{7'}$ together with the carbon to which they are bonded form –C(=O)-;

R^8 is selected from the group consisting of hydrogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, and C_3-C_6cycloalkyl;

R^9 is selected from the group consisting of $-NR^{10}R^{11}$, $[-C(=NR^{12})-NR^{13}]$-$\underline{C(=NR^{12})-NHR^{13}}$, $-N=CR^{14}-NR^{10}R^{11}$, $-NR^{13}-CR^{14}=NR^{12}$, and $[-NR^{13}-C(=NR^{12})-NR^{13}]$-$\underline{NR^{13}-C(=NR^{12})-NHR^{13}}$;

R^{10}, R^{11}, R^{12}, R^{13} and R^{14} are independently selected from the group consisting of hydrogen, hydroxy, hydroxy-C_1-C_6alkyl, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, and C_3-C_7 cycloalkyl; or any member of the group R^{10}, R^{11}, R^{12}, R^{13}, and R^{14} together with the nitrogen to which it is attached forms a 5, 6 or 7 member heterocycle with any other member of the group, the heterocycle optionally containing one additional heteroatom selected from N, O [or]and S;

R^{15} is selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_3-C_7cycloalkyl, aminocarbonyl, C_1-C_6alkylaminocarbonyl, and di(C_1-C_6alkyl)aminocarbonyl; and

R^{16} is selected from the group consisting of hydrogen, C_1-C_6alkyl, C_3-C_{13}cycloalkyl, C_6-C_{10}aryl, acetylamino-C_1-C_{12}alkyl, C_1-C_6alkylcarbonyloxy-C_1-C_6alkyl, and C_6-C_{10}aryl-C_0-C_6alkylcarbonyloxy-C_1-C_6alkyl,

or a pharmaceutically acceptable salt thereof;

provided that the compound is not N-[2-[1-(aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-phenylethynyl-phenylalanine methyl ester or a pharmaceutically acceptable salt thereof.

Amend Claim 5 as follows:

5. (Amended) A compound of claim 1 where R^1 is hydrogen or [lower alkyl](C_1-C_6alkyl).

Amend Claim 6 as follows:

6. (Amended) A compound of claim 1 where R^2 and R^3 are hydrogen, [lower alkyl]C_1-C_6alkyl, cyano, or halo.

Amend Claim 7 as follows:

7. (Amended) A compound of claim 1 where



R^4 is ; [, especially where one or more of the following preferences applies:] Ar is selected from the group consisting of phenyl, furyl, thienyl, oxazolyl, thiazolyl, and pyrrolyl; R^5 is hydroxy, C_1-C_2alkoxy-methoxy [and]or C_1-C_3-alkoxy; Q is [a negatively charged species such as carboxy or a prodrug thereof]–C(=O)OR^{16}, where R^{16} is selected from the group consisting of hydrogen, C_1-C_6alkyl, C_3-C_{13}cycloalkyl, C_6-C_{10}aryl, acetylamino-C_1-C_{12}alkyl, C_1-C_6alkylcarbonyloxy-C_1-C_6alkyl, and C_6-C_{10}aryl-C_0-C_6alkylcarbonyloxy-C_1-C_6alkyl, or Q is[tetrazole]tetrazolyl; and L is –O-, -CH_2-O-, -O-CH_2- or –CH_2-CH_2-O-.

Replace claim 11 with the following substitute claim 11.

11. (Substitute) A compound of claim 1 where M is selected from the group consisting of R^9,



and

















































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and

.